Neurosurgical treatment of bipolar depression: defining treatment resistance and identifying surgical targets

  1. Nir Lipsman1,
  2. Roger S McIntyre2,
  3. Peter Giacobbe2,
  4. Cristina Torres1,
  5. Sidney H Kennedy2,
  6. Andres M Lozano1

Article first published online: 29 OCT 2010

DOI: 10.1111/j.1399-5618.2010.00868.x

Issue

Bipolar Disorders

Bipolar Disorders

Volume 12, Issue 7, pages 691–701, November 2010

Additional Information

How to Cite

Lipsman, N., McIntyre, R. S., Giacobbe, P., Torres, C., Kennedy, S. H. and Lozano, A. M. (2010), Neurosurgical treatment of bipolar depression: defining treatment resistance and identifying surgical targets. Bipolar Disorders, 12: 691–701. doi: 10.1111/j.1399-5618.2010.00868.x

Author Information

  1. 1

    Division of Neurosurgery, University Health Network

  2. 2

    Department of Psychiatry, University of Toronto, University Health Network, Toronto, ON, Canada

*Corresponding author: Nir Lipsman, M.D. Division of Neurosurgery Toronto Western Hospital University Health Network 399 Bathurst Street, 4W-447 Toronto, Ontario M2R 5S8, Canada Fax: 416-603-5298 E-mail: nir.lipsman@utoronto.ca

  1. RSM has received research grants from Eli Lilly & Co., Janssen-Ortho, Shire, and AstraZeneca; and is on the advisory board for AstraZeneca, Bristol-Myers Squibb, the France Foundation, GlaxoSmithKline, Janssen-Ortho, Solvay/Wyeth, Eli Lilly & Co., Organon, Lundbeck, Biovail, Pfizer, Shire, and Schering-Plough. PG has received research funds from Eli Lilly & Co; and is on speaker/advisory boards for AstraZeneca and St. Jude Medical. SHK has received grant funding from AstraZeneca, Brain Cells, Inc., Eli Lilly & Co., GlaxoSmithKline, Janssen Ortho, Lundbeck, and St. Jude Medical; and is an advisor or consultant for Lundbeck, Pfizer, Servier, AstraZeneca, Biovail, Boehringer Ingelheim, Eli Lilly & Co., GlaxoSmithKline, Janssen, St. Jude Medical; and Wyeth Pharmaceuticals. AML is a Tier I Canada Research Chair in Neuroscience; and is a consultant for Medtronic, St. Jude Medical, Eli Lilly & Co., and Boston Scientific. NL and CT have no conflicts of interest to disclose.

Publication History

  1. Issue published online: 29 OCT 2010
  2. Article first published online: 29 OCT 2010
  3. Received 14 February 2010, revised and accepted for publication 31 August 2010

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (191K)

Options for accessing this content:

  • If you have access to this content through a society membership, please first log in to your society website.
  • If you would like institutional access to this content, please recommend the title to your librarian.
  • Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
  • You can purchase online access to this Article for a 24-hour period (price varies by title)
    • If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
    • New Users: Please register, then proceed to purchase the article.

If your institution is a registered Wiley Online Library customer, you can log in under your institution's name to see our content. This access is provided by Shibboleth or Athens.

Type your institution's name in the box below. If your institution is a Wiley customer, it will appear in the list of suggested institutions.

Please register to:

  • Save publications, articles and searches
  • Get email alerts
  • Get all the benefits mentioned below!

Register now >

Get PDF (191K)